Press Releases

European Authorities Approve Advantageous Modifications to Myring™ labelling
8 November 2019
EN FR

Notice of Extraordinary Shareholders Meeting on 29th November 2019
30 October 2019
EN FR

Mithra Signs LSA for Commercialization of Myring™ and Tibelia® in Eastern Europe
24 October 2019
EN FR

Mithra Announces Publication of Estelle® Abstracts in Connection with the 13th Annual Meeting of the European Society of Gynecology
22 October 2019
EN FR

Presentation of Estelle® Phase III results at the 13th Meeting of the European Society of Gynecology
16 October 2019
EN FR

Mithra Signs Agreement for Commercialization of Myring™ in China with Abbott
14 October 2019
EN FR

Mithra Initiates Phase III Clinical Program for Donesta®
9 October 2019
EN FR

Mithra Provides Supplementary Details on Estelle® US Deal with Mayne
3 October 2019
EN FR

Mithra Sucessfully Renegotiates Earnout Payments
1 October 2019
EN FR

Mithra Signs Landmark Contract for Estelle® in the United States with Mayne Pharma
1 October 2019
EN FR

Mithra Announces 2019 Half Year Results
19 September 2019
EN FR

Interim Financial Report as at 30 June 2019
19 September 2019
EN FR

Mithra Signs LSA for Commercialization of Estelle® and Myring™ in Israel
20 August 2019
EN FR

Mithra obtains crucial additional Estelle® patent in Japan
8 August 2019
EN FR

Mithra CDMO Strengthens its Management Team and Accelerates Key R&D Programs
16 July 2019
EN FR

Mithra Signs LSA for Commercialization of Myring™ in Germany, the biggest market in Europe
28 May 2019
EN FR

Tibelia®, First Tibolone-Based Hormone Therapy Approved in Canada
15 May 2019
EN FR

Information on the Total Number of Voting Rights (Denominator)
29 April 2019
EN FR

Mithra Signs License and Supply Agreement for Commercialization of Myring™ in Latin and South America
25 April 2019
EN FR

Mithra announces new agreement with GSP for development of an additional injectable
18 April 2019
EN FR

Mithra Releases 2018 Annual Report and Invitation to its Ordinary General Shareholders’ Meeting
8 April 2019
EN FR

Annual Report 2018
8 April 2019
EN FR

Mithra wins essenscia Innovation Award 2019 for its new generation contraceptive pill, Estelle®
2 April 2019
EN FR

Mithra receives Orphan Drug Designation from FDA for E4 in neonatal encephalopathy treatment
2 April 2019
EN FR

Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society
25 March 2019
EN FR

Mithra Signs License and Supply Agreement for Commercialization of Tibelia® in Chile
5 March 2019
EN FR

Mithra Reports 2018 Annual Results
1 March 2019
EN FR

Mithra Signs Partnership Agreement With Itrom for Commercialization of Estelle® in the Middle East
28 February 2019
EN FR

Information on the Total Number of Voting Rights (Denominator)
25 February 2019
EN FR

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company
20 February 2019
EN FR

Mithra Successfully Produces its First Commercial Batch of Myring™ for Europe
13 February 2019
EN FR

Mithra Signs Exclusive License and Supply Agreement for Commercialization of Myring™ in the Middle East
12 February 2019
EN FR

Mithra Strengthens Management Team With Key Appointments
4 February 2019
EN FR

Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
30 January 2019
EN FR

Mithra announces 2019 financial calendar
22 January 2019
EN FR

Mithra Wins BelMid Company of the Year 2018
18 January 2019
EN FR

Blockbuster Potential in Perimenopause with new E4 Candidate and Acceleration of Donesta Phase III Program
7 January 2019
EN FR

Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference
4 January 2019
EN FR